<?xml version="1.0" encoding="UTF-8"?>
<p>In a subanalysis of groups based on prior TKI before entry into the STAT2 trial, the 12-month TFR rate was 62.5% (95% CI: 45.8–77.3%) in the 'imatinib only' group and 69.7% (95% CI: 51.3–84.4%) in the 'nilotinib following imatinib' group. In another subanalysis based on positivity of molecular residual disease (MRD) before the TFR phase, the 12-month TFR rate was 56.8% (95% CI: 39.5–72.9%) in the MRD group and 78.0% (95% CI: 62.4–89.4%) in the UMRD with MR
 <sup>5</sup> group; the corresponding 24-month TFR rates were 48.6% (95% CI: 31.9–65.6%) and 75.6% (95% CI: 59.7–87.6%).
</p>
